Free Trial
NASDAQ:ASLN

ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis

ASLAN Pharmaceuticals logo
$0.60 0.00 (0.00%)
As of 11/6/2026

About ASLAN Pharmaceuticals Stock (NASDAQ:ASLN)

Advanced

Key Stats

Today's Range
$0.60
▼
$0.60
50-Day Range
$0.60
▼
$0.60
52-Week Range
$0.48
▼
$25.44
Volume
N/A
Average Volume
122,322 shs
Market Capitalization
$1.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) was a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases and cancer. The company was founded in Singapore and operated internationally, with activities spanning the United States, Asia and other global markets.

Its primary development programs included eblasakimab, an investigational monoclonal antibody targeting the interleukin-13 receptor alpha 1 pathway for potential treatment of atopic dermatitis and other inflammatory conditions. ASLAN also developed varlitinib, an investigational small-molecule therapy designed to inhibit certain receptor tyrosine kinases and evaluated in oncology indications.

ASLAN Pharmaceuticals advanced its programs through clinical development and collaborations with research and pharmaceutical organizations. The company later undertook strategic changes that affected its operations and pipeline, and publicly available information about its current activities and leadership is limited.

AI Generated. May Contain Errors.

Receive ASLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ASLN Stock News Headlines

Many investors are about to lose everything
Twenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.tc pixel
See More Headlines

ASLN Stock Analysis - Frequently Asked Questions

ASLAN Pharmaceuticals' stock was trading at $0.60 at the start of the year. Since then, ASLN shares have increased by 0.0% and is now trading at $0.60.

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) issued its earnings results on Friday, August, 11th. The company reported ($0.88) earnings per share for the quarter, topping analysts' consensus estimates of ($6.40) by $5.52. The business earned $12 million during the quarter.

Shares of ASLAN Pharmaceuticals reverse split before market open on Wednesday, July 3rd 2024.The 1-8 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

ASLAN Pharmaceuticals (ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ASLAN Pharmaceuticals investors own include NIO (NIO), Tesla (TSLA), FuelCell Energy (FCEL), Nabriva Therapeutics (NBRV), NVIDIA (NVDA), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

Company Calendar

Today
11/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ASLN
CIK
1722926
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($21.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$44.22 million
Net Margins
N/A
Pretax Margin
-290.83%
Return on Equity
-8,454.87%
Return on Assets
-121.60%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.05
Quick Ratio
1.05

Sales & Book Value

Annual Sales
$12 million
Price / Sales
0.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($6.50) per share
Price / Book
-0.09

Miscellaneous

Outstanding Shares
2,044,000
Free Float
1,948,000
Market Cap
$1.23 million
Optionable
No Data
Beta
1.40

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:ASLN) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners